JP2010510171A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510171A5
JP2010510171A5 JP2009525739A JP2009525739A JP2010510171A5 JP 2010510171 A5 JP2010510171 A5 JP 2010510171A5 JP 2009525739 A JP2009525739 A JP 2009525739A JP 2009525739 A JP2009525739 A JP 2009525739A JP 2010510171 A5 JP2010510171 A5 JP 2010510171A5
Authority
JP
Japan
Prior art keywords
antiviral agent
interferon
use according
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510171A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/076435 external-priority patent/WO2008063727A2/en
Publication of JP2010510171A publication Critical patent/JP2010510171A/ja
Publication of JP2010510171A5 publication Critical patent/JP2010510171A5/ja
Pending legal-status Critical Current

Links

JP2009525739A 2006-08-21 2007-08-21 ウイルス感染症の治療のための併用療法 Pending JP2010510171A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83887206P 2006-08-21 2006-08-21
US87449806P 2006-12-13 2006-12-13
US89430707P 2007-03-12 2007-03-12
PCT/US2007/076435 WO2008063727A2 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2010510171A JP2010510171A (ja) 2010-04-02
JP2010510171A5 true JP2010510171A5 (enExample) 2010-10-14

Family

ID=39426663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525739A Pending JP2010510171A (ja) 2006-08-21 2007-08-21 ウイルス感染症の治療のための併用療法

Country Status (6)

Country Link
US (2) US20080131398A1 (enExample)
EP (1) EP2054076A2 (enExample)
JP (1) JP2010510171A (enExample)
KR (1) KR20090057035A (enExample)
CA (1) CA2666814A1 (enExample)
WO (1) WO2008063727A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049126A2 (en) * 2006-08-02 2009-04-22 United Therapeutics Corporation Liposome treatment of viral infections
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
CA2753194A1 (en) * 2009-02-24 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
JP5752689B2 (ja) * 2009-09-04 2015-07-22 ユナイテッド セラピューティクス コーポレイション フィロウイルス疾患を治療するイミノ糖および方法
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
JP2015536950A (ja) 2012-11-02 2015-12-24 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190191740A1 (en) * 2016-06-23 2019-06-27 Nutrivert Llc Methods to Promote Growth and Improve Feed Conversion in Animals
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
AU2019356014A1 (en) 2018-10-05 2021-05-20 Alexis Bio, Inc. Xenotransplantation products and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) * 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
DE2834122A1 (de) * 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
DE2853573A1 (de) * 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4350155A (en) * 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4531937A (en) * 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US4861892A (en) * 1988-02-12 1989-08-29 G. D. Searle & Co. Method for synthesis of deoxymannojirimycin
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4855173A (en) * 1988-08-11 1989-08-08 Dore Peter B Repair process for a fibre reinforced structure
US4910310A (en) * 1988-10-03 1990-03-20 G. D. Searle & Co. Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
US4894388A (en) * 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
US5011929A (en) * 1989-05-15 1991-04-30 Monsanto Company Synthesis of mannojirimycin derivatives
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US4996329A (en) * 1989-10-20 1991-02-26 Monsanto Company Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5151519A (en) * 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
DK0477160T3 (da) * 1990-09-20 1996-05-20 Monsanto Co Fremgangsmåde til fremstilling af N-substitueret 1-deoxynojirimycin
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5401645A (en) * 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5286877A (en) * 1993-02-01 1994-02-15 G. D. Searle & Co. Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT739205E (pt) * 1994-01-13 2000-04-28 Monsanto Co Utilizacao de derivados de 1,5-didesoxi-1,5-imino-d-glucitol para o tratamento de infeccoes com o virus da hepatite b
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5443450A (en) * 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
DE19509634C1 (de) * 1995-03-17 1996-03-28 Fresenius Ag Implantierbare Infusionspumpe
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ATE235224T1 (de) * 1996-02-02 2003-04-15 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
IN183120B (enExample) * 1996-10-18 1999-09-11 Vertex Pharma
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
GB2324223A (en) * 1997-04-11 1998-10-14 Northern Telecom Ltd Network management
US6171276B1 (en) * 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
ATE234103T1 (de) * 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
JP4690545B2 (ja) * 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6440985B1 (en) * 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) * 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
AU3595500A (en) * 1999-02-12 2000-08-29 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6198966B1 (en) * 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
EP1261339A1 (en) * 2000-02-14 2002-12-04 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
WO2001072707A2 (en) * 2000-03-29 2001-10-04 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
TR200200767T1 (tr) * 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
DE10031274A1 (de) * 2000-06-27 2002-01-10 Bosch Gmbh Robert Wischarm für Kraftfahrzeuge
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
AU2002348971A1 (en) * 2001-10-12 2003-04-28 Stefana M. Petrescu Ph-sensitive liposomes for targeted drug delivery
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US20060052414A1 (en) * 2004-08-13 2006-03-09 Migenix, Inc. Compositions and methods for treating or preventing Hepadnaviridae infection
EA200700718A1 (ru) * 2004-10-06 2007-12-28 Мидженикс Инк. Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20060194835A1 (en) * 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
EP2049126A2 (en) * 2006-08-02 2009-04-22 United Therapeutics Corporation Liposome treatment of viral infections

Similar Documents

Publication Publication Date Title
JP2010510171A5 (enExample)
Kurimoto et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities
JP2010514786A5 (enExample)
JP2004516314A5 (enExample)
JP2014513954A5 (enExample)
JP2007534636A5 (enExample)
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
JP2009526034A5 (enExample)
JP2006524225A5 (enExample)
KR20110054056A (ko) 마크로사이클릭 ｈｃｖ 저해제 및 뉴클레오시드의 상승적 배합물
JP2006512313A5 (enExample)
JP2015512860A5 (enExample)
JP2004534769A5 (enExample)
JP2005511699A5 (enExample)
JP2013538235A5 (enExample)
JP2007530577A5 (enExample)
JP2010504343A5 (enExample)
JP2005511531A5 (enExample)
WO2006120251A1 (en) Pteridines useful as hcv inhibitors and methods for the preparation thereof
JP2012519691A5 (enExample)
JP2018135343A5 (enExample)
JP2010501478A5 (enExample)
JP2002543114A5 (enExample)
JP2012502048A5 (enExample)
JP2002543144A5 (enExample)